Ameriprise
INDV icon

Ameriprise’s Indivior Pharmaceuticals INDV Stock Holding History

Ameriprise’s Portfolio INDV Stock Details INDV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$6.31M Sell
206,879
-23,271
-10% -$769K ﹤0.01% 2283
2025
Q4 		$8.26M Buy
230,150
+200,700
+681% +$6.13M ﹤0.01% 2063
2025
Q3 		$710K Buy
+29,450
New +$616K ﹤0.01% 3498

Other funds holding INDV

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
OCM
Oaktree Capital Management Los Angeles, California $6.56B AUM 42.97% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Ameriprise's INDV Position: Q1 2026 in Review

Ameriprise reduced its Indivior Pharmaceuticals (INDV) stake by 10% in Q1 2026, selling an estimated $769K and leaving 206,879 shares worth $6.31M. The position accounts for ﹤0.01% of the portfolio, ranked #2283.

Ameriprise first reported a position in INDV in Q3 2025 and has held it in 3 quarters since. The position peaked at $8.26M in Q4 2025. 289 funds tracked by Wall St. Rank hold INDV as of Q1 2026.

  • Ameriprise held 206,879 shares of Indivior Pharmaceuticals worth $6.31M as of Q1 2026.
  • Ameriprise sold 23,271 Indivior Pharmaceuticals shares in Q1 2026, an estimated $769K.
  • Indivior Pharmaceuticals made up ﹤0.01% of Ameriprise's portfolio in Q1 2026, its #2283 holding.
  • Ameriprise first reported a position in Indivior Pharmaceuticals in Q3 2025 and has held it in 3 quarters since.
  • Ameriprise's Indivior Pharmaceuticals position peaked at $8.26M in Q4 2025.
  • 289 funds tracked by Wall St. Rank held Indivior Pharmaceuticals as of Q1 2026.

Based on Ameriprise's 13F filing for Q1 2026, filed 15 May 2026.